title: CGS 19755: a novel competitive N-methyl-D-aspartate (NMDA) receptor antagonist with anticonvulsant, anxiolytic and anti-ischemic properties.
abstract: CGS 19755 is a potent and selective competitive antagonist at NMDA receptors in the brain. In preclinical animal tests, the compound produces anticonvulsant, anxiolytic and anti-ischemic effects. CGS 19755 is not very active when administered orally, and intravenous administration is the most practical for clinical application. The anti-ischemic potential of CGS 19755 provides the most attractive application for clinical investigation.
authors.affiliation: Research Department, CIBA-Geigy Corporation, Summit, NJ 07901.
authors.forename: D A
authors.initials: DA
authors.lastname: Bennett
authors.forename: J
authors.initials: J
authors.lastname: Lehmann
authors.forename: P S
authors.initials: PS
authors.lastname: Bernard
authors.forename: J M
authors.initials: JM
authors.lastname: Liebman
authors.forename: M
authors.initials: M
authors.lastname: Williams
authors.forename: P L
authors.initials: PL
authors.lastname: Wood
authors.forename: C A
authors.initials: CA
authors.lastname: Boast
authors.forename: A J
authors.initials: AJ
authors.lastname: Hutchison
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D000927:Anticonvulsants / Q000494:pharmacology; D001667:Binding, Competitive; D007511:Ischemia / Q000188:drug therapy; D010875:Pipecolic Acids / Q000494:pharmacology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors
chemical_list: D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D010875:Pipecolic Acids; D016194:Receptors, N-Methyl-D-Aspartate; C053672:selfotel